{"transactions":[{"id":4133794,"issuer":{"id":171193,"kind":"organization","name":"Ocera Therapeutics, Inc.","symbol":"OCRX"},"owners":[{"id":164155,"kind":"organization","name":"DOMAIN ASSOCIATES","position":1,"cik":"0001020733","reported_name":"DOMAIN ASSOCIATES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":138386,"kind":"person","name":"BLAIR JAMES C","position":2,"cik":"0001024000","reported_name":"BLAIR JAMES C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":153843,"kind":"person","name":"DOVEY BRIAN H","position":3,"cik":"0001207786","reported_name":"DOVEY BRIAN H","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":148535,"kind":"person","name":"TREU JESSE I","position":4,"cik":"0001013425","reported_name":"TREU JESSE I","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":79004,"kind":"person","name":"VITULLO NICOLE","position":5,"cik":"0001196863","reported_name":"VITULLO NICOLE","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120873,"kind":"person","name":"Halak Brian K","position":6,"cik":"0001354718","reported_name":"Halak Brian K","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30494,"kind":"person","name":"Kamdar Kim P.","position":7,"cik":"0001535065","reported_name":"Kamdar Kim P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-12-13T16:58:46.000Z","date":"2017-12-11","kind":"disposition_to_issuer","acquired":false,"shares":47963,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to an Agreement and Plan of Merger, dated November 1, 2017 (the \"Merger Agreement\"), by and between the Issuer, MAK LLC, a Delaware limited liability company (\"Parent\"), MEH Acquisition Co., a Delaware corporation and a direct wholly-owned subsidiary of Parent (\"Purchaser\"), and for limited purposes, Mallinckrodt plc, an Irish public limited company and the ultimate parent entity of Parent and Purchaser (\"Mallinckrodt\"), Purchaser was merged with and into the Issuer on December 11, 2017, with the Issuer surviving as a wholly-owned subsidiary of Parent (the \"Merger\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from Footnote 1) Pursuant to the terms of the Merger Agreement, all shares Common Stock of the Issuer outstanding immediately prior to the effective time of the Merger were canceled and converted automatically into the right to receive (i) $1.52 per share in cash, plus (ii) one non-transferable contingent value right per Share (each, a \"CVR\"), which represents the contractual right under a contingent value rights agreement, by and among Parent, Continental Stock Transfer & Trust Company, and for limited purposes, Mallinckrodt, entered into on December 7, 2017, to receive one or more payments in cash currently estimated to be up to $2.58 per share, contingent upon the achievement of certain milestones, in each case, less any required withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to an Agreement and Plan of Merger, dated November 1, 2017 (the \"Merger Agreement\"), by and between the Issuer, MAK LLC, a Delaware limited liability company (\"Parent\"), MEH Acquisition Co., a Delaware corporation and a direct wholly-owned subsidiary of Parent (\"Purchaser\"), and for limited purposes, Mallinckrodt plc, an Irish public limited company and the ultimate parent entity of Parent and Purchaser (\"Mallinckrodt\"), Purchaser was merged with and into the Issuer on December 11, 2017, with the Issuer surviving as a wholly-owned subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) Pursuant to the terms of the Merger Agreement, all shares Common Stock of the Issuer outstanding immediately prior to the effective time of the Merger were canceled and converted automatically into the right to receive (i) $1.52 per share in cash, plus (ii) one non-transferable contingent value right per Share (each, a \"CVR\"), which represents the contractual right under a contingent value rights agreement, by and among Parent, Continental Stock Transfer & Trust Company, and for limited purposes, Mallinckrodt, entered into on December 7, 2017, to receive one or more payments in cash currently estimated to be up to $2.58 per share, contingent upon the achievement of certain milestones, in each case, less any required withholding taxes."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"The securities reported as directly beneficially owned by the designated Reporting Person may be deemed to be indirectly beneficially owned by each of the Reporting Owners listed below, each of whom is a managing member of the designated Reporting Person. Pursuant to Instruction 4(b)(iv) of Form 4, each such individual has elected to report as indirectly beneficially owned the entire number of securities owned by the designated Reporting Person, however each of them disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed his or her pecuniary interest therein and/or that are not actually distributed to him or her."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000904454-17-000727","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1013425/000090445417000727/edgar.xml","form_type":"4"}},{"id":4566961,"issuer":{"id":181299,"kind":"organization","name":"Tobira Therapeutics, Inc.","symbol":"TBRA"},"owners":[{"id":164155,"kind":"organization","name":"DOMAIN ASSOCIATES","position":1,"cik":"0001020733","reported_name":"DOMAIN ASSOCIATES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":138386,"kind":"person","name":"BLAIR JAMES C","position":2,"cik":"0001024000","reported_name":"BLAIR JAMES C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":153843,"kind":"person","name":"DOVEY BRIAN H","position":3,"cik":"0001207786","reported_name":"DOVEY BRIAN H","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":148535,"kind":"person","name":"TREU JESSE I","position":4,"cik":"0001013425","reported_name":"TREU JESSE I","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":79004,"kind":"person","name":"VITULLO NICOLE","position":5,"cik":"0001196863","reported_name":"VITULLO NICOLE","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120873,"kind":"person","name":"Halak Brian K","position":6,"cik":"0001354718","reported_name":"Halak Brian K","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30494,"kind":"person","name":"Kamdar Kim P.","position":7,"cik":"0001535065","reported_name":"Kamdar Kim P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2016-11-04T08:30:57.000Z","date":"2016-11-01","kind":"disposition_to_issuer","acquired":true,"shares":17695,"ownership":{"direct":false,"nature":"Held by Jesse I. Treu"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the merger described above, each outstanding option to purchase Common Stock which had an  exercise price less than $28.35 per share was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) $28.35 over (y) the exercise price per share, multiplied by (B) the total number of shares subject to such option immediately prior to the effective time of the merger and (ii) a contingent value right with respect to the total number of shares subject to such option immediately prior to the effective time of the merger."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Each other outstanding option to purchase Common Stock was cancelled and converted into the right to receive a cash payment, if any, from Allergan Holdco US, Inc. with respect to each share subject to such option upon each date that a payment would be required to a holder of a contingent value right under the terms of the  contingent value rights agreement that was entered into in connection with the merger agreement on or prior to the fifth anniversary of the effective time of the merger."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the merger described above, each outstanding option to purchase Common Stock which had an  exercise price less than $28.35 per share was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) $28.35 over (y) the exercise price per share, multiplied by (B) the total number of shares subject to such option immediately prior to the effective time of the merger and (ii) a contingent value right with respect to the total number of shares subject to such option immediately prior to the effective time of the merger."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Each other outstanding option to purchase Common Stock was cancelled and converted into the right to receive a cash payment, if any, from Allergan Holdco US, Inc. with respect to each share subject to such option upon each date that a payment would be required to a holder of a contingent value right under the terms of the  contingent value rights agreement that was entered into in connection with the merger agreement on or prior to the fifth anniversary of the effective time of the merger."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the merger described above, each outstanding option to purchase Common Stock which had an  exercise price less than $28.35 per share was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) $28.35 over (y) the exercise price per share, multiplied by (B) the total number of shares subject to such option immediately prior to the effective time of the merger and (ii) a contingent value right with respect to the total number of shares subject to such option immediately prior to the effective time of the merger."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Each other outstanding option to purchase Common Stock was cancelled and converted into the right to receive a cash payment, if any, from Allergan Holdco US, Inc. with respect to each share subject to such option upon each date that a payment would be required to a holder of a contingent value right under the terms of the  contingent value rights agreement that was entered into in connection with the merger agreement on or prior to the fifth anniversary of the effective time of the merger."}],"balance_after":0,"derivative":{"exercise_price":8.19,"underlying":"Common Stock","underlying_shares":17695},"source":{"system":"sec-edgar","filing":"0000904454-16-001535","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1013425/000090445416001535/edgar.xml","form_type":"4"}},{"id":4566960,"issuer":{"id":181299,"kind":"organization","name":"Tobira Therapeutics, Inc.","symbol":"TBRA"},"owners":[{"id":164155,"kind":"organization","name":"DOMAIN ASSOCIATES","position":1,"cik":"0001020733","reported_name":"DOMAIN ASSOCIATES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":138386,"kind":"person","name":"BLAIR JAMES C","position":2,"cik":"0001024000","reported_name":"BLAIR JAMES C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":153843,"kind":"person","name":"DOVEY BRIAN H","position":3,"cik":"0001207786","reported_name":"DOVEY BRIAN H","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":148535,"kind":"person","name":"TREU JESSE I","position":4,"cik":"0001013425","reported_name":"TREU JESSE I","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":79004,"kind":"person","name":"VITULLO NICOLE","position":5,"cik":"0001196863","reported_name":"VITULLO NICOLE","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120873,"kind":"person","name":"Halak Brian K","position":6,"cik":"0001354718","reported_name":"Halak Brian K","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30494,"kind":"person","name":"Kamdar Kim P.","position":7,"cik":"0001535065","reported_name":"Kamdar Kim P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2016-11-04T08:30:57.000Z","date":"2016-11-01","kind":"disposition_to_issuer","acquired":true,"shares":1071,"ownership":{"direct":false,"nature":"Held by Jesse I. Treu"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the merger described above, each outstanding option to purchase Common Stock which had an  exercise price less than $28.35 per share was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) $28.35 over (y) the exercise price per share, multiplied by (B) the total number of shares subject to such option immediately prior to the effective time of the merger and (ii) a contingent value right with respect to the total number of shares subject to such option immediately prior to the effective time of the merger."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Each other outstanding option to purchase Common Stock was cancelled and converted into the right to receive a cash payment, if any, from Allergan Holdco US, Inc. with respect to each share subject to such option upon each date that a payment would be required to a holder of a contingent value right under the terms of the  contingent value rights agreement that was entered into in connection with the merger agreement on or prior to the fifth anniversary of the effective time of the merger."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the merger described above, each outstanding option to purchase Common Stock which had an  exercise price less than $28.35 per share was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) $28.35 over (y) the exercise price per share, multiplied by (B) the total number of shares subject to such option immediately prior to the effective time of the merger and (ii) a contingent value right with respect to the total number of shares subject to such option immediately prior to the effective time of the merger."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Each other outstanding option to purchase Common Stock was cancelled and converted into the right to receive a cash payment, if any, from Allergan Holdco US, Inc. with respect to each share subject to such option upon each date that a payment would be required to a holder of a contingent value right under the terms of the  contingent value rights agreement that was entered into in connection with the merger agreement on or prior to the fifth anniversary of the effective time of the merger."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the merger described above, each outstanding option to purchase Common Stock which had an  exercise price less than $28.35 per share was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) $28.35 over (y) the exercise price per share, multiplied by (B) the total number of shares subject to such option immediately prior to the effective time of the merger and (ii) a contingent value right with respect to the total number of shares subject to such option immediately prior to the effective time of the merger."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Each other outstanding option to purchase Common Stock was cancelled and converted into the right to receive a cash payment, if any, from Allergan Holdco US, Inc. with respect to each share subject to such option upon each date that a payment would be required to a holder of a contingent value right under the terms of the  contingent value rights agreement that was entered into in connection with the merger agreement on or prior to the fifth anniversary of the effective time of the merger."}],"balance_after":0,"derivative":{"exercise_price":42.93,"underlying":"Common Stock","underlying_shares":1071},"source":{"system":"sec-edgar","filing":"0000904454-16-001535","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1013425/000090445416001535/edgar.xml","form_type":"4"}},{"id":4566959,"issuer":{"id":181299,"kind":"organization","name":"Tobira Therapeutics, Inc.","symbol":"TBRA"},"owners":[{"id":164155,"kind":"organization","name":"DOMAIN ASSOCIATES","position":1,"cik":"0001020733","reported_name":"DOMAIN ASSOCIATES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":138386,"kind":"person","name":"BLAIR JAMES C","position":2,"cik":"0001024000","reported_name":"BLAIR JAMES C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":153843,"kind":"person","name":"DOVEY BRIAN H","position":3,"cik":"0001207786","reported_name":"DOVEY BRIAN H","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":148535,"kind":"person","name":"TREU JESSE I","position":4,"cik":"0001013425","reported_name":"TREU JESSE I","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":79004,"kind":"person","name":"VITULLO NICOLE","position":5,"cik":"0001196863","reported_name":"VITULLO NICOLE","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120873,"kind":"person","name":"Halak Brian K","position":6,"cik":"0001354718","reported_name":"Halak Brian K","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30494,"kind":"person","name":"Kamdar Kim P.","position":7,"cik":"0001535065","reported_name":"Kamdar Kim P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2016-11-04T08:30:57.000Z","date":"2016-11-01","kind":"disposition_to_issuer","acquired":true,"shares":1996,"ownership":{"direct":false,"nature":"Held by Jesse I. Treu"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the merger described above, each outstanding option to purchase Common Stock which had an  exercise price less than $28.35 per share was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) $28.35 over (y) the exercise price per share, multiplied by (B) the total number of shares subject to such option immediately prior to the effective time of the merger and (ii) a contingent value right with respect to the total number of shares subject to such option immediately prior to the effective time of the merger."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Each other outstanding option to purchase Common Stock was cancelled and converted into the right to receive a cash payment, if any, from Allergan Holdco US, Inc. with respect to each share subject to such option upon each date that a payment would be required to a holder of a contingent value right under the terms of the  contingent value rights agreement that was entered into in connection with the merger agreement on or prior to the fifth anniversary of the effective time of the merger."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the merger described above, each outstanding option to purchase Common Stock which had an  exercise price less than $28.35 per share was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) $28.35 over (y) the exercise price per share, multiplied by (B) the total number of shares subject to such option immediately prior to the effective time of the merger and (ii) a contingent value right with respect to the total number of shares subject to such option immediately prior to the effective time of the merger."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Each other outstanding option to purchase Common Stock was cancelled and converted into the right to receive a cash payment, if any, from Allergan Holdco US, Inc. with respect to each share subject to such option upon each date that a payment would be required to a holder of a contingent value right under the terms of the  contingent value rights agreement that was entered into in connection with the merger agreement on or prior to the fifth anniversary of the effective time of the merger."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the merger described above, each outstanding option to purchase Common Stock which had an  exercise price less than $28.35 per share was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) $28.35 over (y) the exercise price per share, multiplied by (B) the total number of shares subject to such option immediately prior to the effective time of the merger and (ii) a contingent value right with respect to the total number of shares subject to such option immediately prior to the effective time of the merger."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Each other outstanding option to purchase Common Stock was cancelled and converted into the right to receive a cash payment, if any, from Allergan Holdco US, Inc. with respect to each share subject to such option upon each date that a payment would be required to a holder of a contingent value right under the terms of the  contingent value rights agreement that was entered into in connection with the merger agreement on or prior to the fifth anniversary of the effective time of the merger."}],"balance_after":0,"derivative":{"exercise_price":36,"underlying":"Common Stock","underlying_shares":1996},"source":{"system":"sec-edgar","filing":"0000904454-16-001535","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1013425/000090445416001535/edgar.xml","form_type":"4"}},{"id":4566958,"issuer":{"id":181299,"kind":"organization","name":"Tobira Therapeutics, Inc.","symbol":"TBRA"},"owners":[{"id":164155,"kind":"organization","name":"DOMAIN ASSOCIATES","position":1,"cik":"0001020733","reported_name":"DOMAIN ASSOCIATES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":138386,"kind":"person","name":"BLAIR JAMES C","position":2,"cik":"0001024000","reported_name":"BLAIR JAMES C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":153843,"kind":"person","name":"DOVEY BRIAN H","position":3,"cik":"0001207786","reported_name":"DOVEY BRIAN H","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":148535,"kind":"person","name":"TREU JESSE I","position":4,"cik":"0001013425","reported_name":"TREU JESSE I","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":79004,"kind":"person","name":"VITULLO NICOLE","position":5,"cik":"0001196863","reported_name":"VITULLO NICOLE","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120873,"kind":"person","name":"Halak Brian K","position":6,"cik":"0001354718","reported_name":"Halak Brian K","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30494,"kind":"person","name":"Kamdar Kim P.","position":7,"cik":"0001535065","reported_name":"Kamdar Kim P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2016-11-04T08:30:57.000Z","date":"2016-11-01","kind":"other","acquired":false,"shares":38094,"price":28.35,"value":1079964.9,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the terms of a merger agreement, pursuant to which the Issuer was acquired by Allergan Holdco US, Inc., the shares were tendered for $28.35 per share in cash plus one non-transferable contingent value right per share, which represents the contractual right to receive one or more payments in cash of up to $49.84 per share in the aggregate, contingent upon the achievement of certain milestones."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities reported as directly beneficially owned by the designated Reporting Person may be deemed to be indirectly benefically owned by each of the Reporting Owners listed below, each of whom is a managing member of the designated Reporting Person.  Pursuant to Instruction 4(b)(iv) of Form 4, each such individual has elected to report as indirectly beneficially owned the entire number of securities owned by the designated Reporting Person, however each of them disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed his or her pecuniary interest therein and/or that are not actually distributed to him or her."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000904454-16-001535","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1013425/000090445416001535/edgar.xml","form_type":"4"}}]}